Vanta Bioscience Limited (BOM:540729)
India · Delayed Price · Currency is INR 21.55
+1.02 (4.97%)
At close: Sep 29, 2026
Vanta Bioscience Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 18.16 | 18.16 | 11.27 | 97.23 | 62.76 | 100.18 |
Revenue Growth | 47.09% | 61.11% | -88.40% | 54.93% | -37.35% | -0.33% |
Gross Profit Gross Profit Growth | 26.76 | 26.76 | 0.12 | 88.74 | 52.85 | 92.03 |
Operating Income Operating Income Growth | 6.32 | 6.32 | -21.07 | -31.68 | -50.64 | 24.83 |
Net Income Net Income Growth | 1.08 | 1.08 | -26.71 | -23.16 | -64.81 | 0.88 |
Earnings Per Share EPS Growth | 0.15 | 0.15 | -4.23 | -3.67 | -10.27 | 0.14 |
EPS Growth | - | - | - | - | - | -80.38% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
India India Growth | 15.64 | 15.64 | 2.52 | 19.91 | 41.23 | 23.79 |
Export Export Growth | 2.31 | 2.31 | 8.76 | 77.32 | 21.53 | 53.47 |
Unallocated Unallocated Growth | 0.22 | 0.22 | - | - | - | 19.62 |
Total Total Growth | 18.16 | 18.16 | 11.27 | 97.23 | 62.76 | 96.87 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 1.35 | 1.35 | 1.48 | 1.61 | 0.97 | 2.24 |
Total Debt Total Debt Growth | 380.78 | 380.78 | 304.71 | 609.54 | 571.61 | 448.67 |
Net Cash (Debt) Net Cash Growth | -379.43 | -379.43 | -303.24 | -607.93 | -570.65 | -446.43 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -53.35 | -53.35 | -48.04 | -96.31 | -90.41 | -70.73 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -52.19 | -52.19 | 13.61 | 26.84 | -6.28 | 52.79 |
Capital Expenditures CapEx Growth | -68.72 | -68.72 | -57.9 | -34.05 | -286.89 | -171.81 |
Free Cash Flow Free Cash Flow Growth | -120.92 | -120.92 | -44.29 | -7.21 | -293.17 | -119.02 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 147.30% | 147.30% | 1.05% | 91.27% | 84.21% | 91.86% |
Operating Margin | 34.77% | 34.77% | -186.90% | -32.58% | -80.69% | 24.78% |
Pretax Margin | 0.75% | 0.75% | -242.19% | -90.78% | -163.53% | 2.28% |
Profit Margin | 5.96% | 5.96% | -236.90% | -23.82% | -103.26% | 0.88% |
FCF Margin | -665.71% | -665.71% | -392.87% | -7.41% | -467.13% | -118.81% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 143.67 | 88.34 | - | - | - | 786.08 |
PS Ratio | 8.44 | 5.27 | 12.38 | 4.16 | 5.78 | 6.92 |